FacebookTwitterYouTubeInstagramLinkedInEmail

New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors Not yet [...]

By |2018-05-07T18:28:13-04:00June 5th, 2016|Clinical Trial|Comments Off on New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
Read More

Patient Survey: pCODR Patient Advocacy Group Input on a Drug Review for Everolimus (Afinitor): Indication for Gastrointestinal and Lung Neuroendocrine Tumours

The Pan-Canadian Oncology Drug Review (pCODR) will be considering an application for the drug Everolimus (Afinitor) indicated for Gastrointestinal and Lung Neuroendocrine (NET) Tumours.  Everolimus is a cancer medicine that [...]

By |2018-05-07T18:28:13-04:00April 16th, 2016|Treatment News|Comments Off on Patient Survey: pCODR Patient Advocacy Group Input on a Drug Review for Everolimus (Afinitor): Indication for Gastrointestinal and Lung Neuroendocrine Tumours
Read More

PRRT clinical trial at CHU de Québec

We are pleased to announce that this week, we are officially launching our 177Lu-octreotate PRRT clinical trial at CHU de Québec, which is called: Personalized Peptide Receptor Radionuclide Therapy of [...]

By |2018-05-07T18:28:14-04:00April 12th, 2016|Treatment News|Comments Off on PRRT clinical trial at CHU de Québec
Read More
Go to Top